Novartis wins EU approval for SMA gene therapy in older patients
Go back to Novartis wins EU approval for SMA gene therapy in older patients| NOVARTIS AG (NYSE: NVS) | Delayed: 155.41 -0.73 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.14 | 52 Week High | $89.15 | |||
| Open | $156.11 | 52 Week Low | $69.84 | |||
| Day High | $156.38 | P/E | N/A | |||
| Day Low | $154.44 | EPS | $0.00 | |||
| Volume | 956,115 | |||||
